The long term goal ofthis research is to elucidate the molecular mechanism by which phospholamban (PLB) inhibits the Capump (SERCAaa isoform) in cardiac sarcoplasmic reticulum (SR). PLBis a pentameric phosphoprotein of five identical monomers in cardiac SR. The PLBmonomer is responsible for binding to SERCAaa and inhibiting it. Wepropose to localize the binding-interaction sites between the PLB monomer and SERCA2a that lead to enzymeinhibition, and to determine howthis protein interaction is regulated by key allosteric modulators including Ca concentration, nucleotides, and PLBphosphorylation. Emphasis will be placed upon identifying aminoacids within the inhibited complex that interact directly,taking advantage of our newlydeveloped chemical cross-linking method.
In Aim i, we will perform Cys-scanning mutagenesis of PLBto localize distinct sites along its primary structure that cross-link to endogenousCys residues of SERCA2a.
In Aim 2, Lysresidues of SERCA2a that cross-link to distinct sites of PLBwill be localized. Using cross-linking agents as molecular rulers, we willthen develop an accurate 3-D model of the quaternary structure ofthe PLBmonomer bound to SERCA2a.
In Aim 3, the effects of Caconcentration, nucleotides, and the inhibitor thapsigargin on cross-linking of PLBto SERCAaa will be investigated. The hypothesis tested is that PLB binds exclusivelyto the Ca-free form (?2) of SERCA2a, but only?2 stabilized by nucleotides CE2-ATP).
In Aim 4, we will determine how Ca reverses PLBinhibition of SERCA2a. We propose that PLBand Cabinding to SERCA2a are mutually exclusive. Cabinding to El favors global dissociation of PLBfrom .E2-ATP, thus allowingthe Capump to be freely active and transport Ca at the maximal rate. The Ca-binding site of SERCAaa responsible for dissociating PLBwillbe identified, and the effect of PLB on the Ca-bindingaffinity of SERCA2a willbe quantified.
In Aim 5, we will determine how phosphorylation of PLB by protein kinases reverses PLBinhibition. The hypothesis tested is that phosphorylation of PLBby protein kinases causes it to fully dissociate from SERCA2a at low ionizedCa concentration, thus allowing Catransport to proceed unencumbered. PLBis a key regulator of cardiac contractility. Bydefining its molecular mechanism of action, new insights on PLBregulation of the strength of the heartbeat will result, whichmay ultimately lead to the design of new drugs to treat heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL049428-19
Application #
8302311
Study Section
Special Emphasis Panel (NSS)
Program Officer
Wong, Renee P
Project Start
1993-01-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
19
Fiscal Year
2012
Total Cost
$533,420
Indirect Cost
$180,162
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Sirenko, Syevda; Maltsev, Victor A; Maltseva, Larissa A et al. (2014) Sarcoplasmic reticulum Ca2+ cycling protein phosphorylation in a physiologic Ca2+ milieu unleashes a high-power, rhythmic Ca2+ clock in ventricular myocytes: relevance to arrhythmias and bio-pacemaker design. J Mol Cell Cardiol 66:106-15
Akin, Brandy L; Hurley, Thomas D; Chen, Zhenhui et al. (2013) The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum. J Biol Chem 288:30181-91
Chen, Zhenhui; Akin, Brandy L; Jones, Larry R (2010) Ca2+ binding to site I of the cardiac Ca2+ pump is sufficient to dissociate phospholamban. J Biol Chem 285:3253-60
Akin, Brandy L; Chen, Zhenhui; Jones, Larry R (2010) Superinhibitory phospholamban mutants compete with Ca2+ for binding to SERCA2a by stabilizing a unique nucleotide-dependent conformational state. J Biol Chem 285:28540-52
Chopra, Nagesh; Yang, Tao; Asghari, Parisa et al. (2009) Ablation of triadin causes loss of cardiac Ca2+ release units, impaired excitation-contraction coupling, and cardiac arrhythmias. Proc Natl Acad Sci U S A 106:7636-41
Chen, Zhenhui; Akin, Brandy L; Jones, Larry R (2007) Mechanism of reversal of phospholamban inhibition of the cardiac Ca2+-ATPase by protein kinase A and by anti-phospholamban monoclonal antibody 2D12. J Biol Chem 282:20968-76
Chen, Zhenhui; Akin, Brandy L; Stokes, David L et al. (2006) Cross-linking of C-terminal residues of phospholamban to the Ca2+ pump of cardiac sarcoplasmic reticulum to probe spatial and functional interactions within the transmembrane domain. J Biol Chem 281:14163-72
Chen, Zhenhui; Stokes, David L; Jones, Larry R (2005) Role of leucine 31 of phospholamban in structural and functional interactions with the Ca2+ pump of cardiac sarcoplasmic reticulum. J Biol Chem 280:10530-9
Waggoner, Jason R; Huffman, Jamie; Griffith, Brian N et al. (2004) Improved expression and characterization of Ca2+-ATPase and phospholamban in High-Five cells. Protein Expr Purif 34:56-67
Chen, Zhenhui; Stokes, David L; Rice, William J et al. (2003) Spatial and dynamic interactions between phospholamban and the canine cardiac Ca2+ pump revealed with use of heterobifunctional cross-linking agents. J Biol Chem 278:48348-56

Showing the most recent 10 out of 28 publications